Does amlodipine (calcium channel blocker) besylate cause bradycardia (abnormally slow heart rate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Does Amlodipine Besylate Cause Bradycardia?

Amlodipine besylate does not cause bradycardia at therapeutic doses. Unlike non-dihydropyridine calcium channel blockers (verapamil, diltiazem), amlodipine has minimal effects on cardiac conduction tissue and does not affect sinoatrial nodal function or atrioventricular conduction 1.

Mechanism and Electrophysiologic Effects

  • Amlodipine is a dihydropyridine calcium channel blocker that acts primarily as a peripheral arterial vasodilator, with no significant negative chronotropic effects 1.

  • The FDA drug label explicitly states that amlodipine does not change sinoatrial nodal function or atrioventricular conduction in intact animals or humans 1.

  • In clinical studies where amlodipine was administered with beta-blockers to patients with hypertension or angina, no adverse effects on electrocardiographic parameters were observed, and no higher degrees of AV blocks occurred 1.

  • Chronic oral administration of amlodipine in clinical trials did not lead to clinically significant changes in heart rate, unlike the acute intravenous administration which may transiently increase heart rate 1.

Contrast with Non-Dihydropyridine Calcium Channel Blockers

  • Verapamil is contraindicated in pulmonary arterial hypertension specifically because of its tendency to cause bradycardia, along with its negative inotropic effects 2.

  • Diltiazem may lower heart rate and is noted to cause bradycardia more than other calcium channel blockers 2.

  • Caution should be exercised when combining non-dihydropyridine calcium channel blockers (verapamil, diltiazem) with beta-blockers due to risk of bradycardia and AV block, but this concern does not apply to amlodipine 2.

Bradycardia Only Occurs in Overdose Situations

  • Bradycardia with amlodipine is documented only in massive overdose cases, not with therapeutic dosing 3, 4, 5.

  • In a case report of a patient who ingested 250 mg of amlodipine (50 tablets of 5 mg), refractory bradycardia occurred with a heart rate of 45 bpm and required isoproterenol infusion for treatment 3.

  • Combined overdose of amlodipine with atenolol (a beta-blocker) causes severe bradycardia and cardiovascular collapse, but this represents the additive effect of the beta-blocker, not amlodipine alone 4, 5.

Clinical Implications

  • When evaluating a patient with bradycardia, focus on beta-blockers, non-dihydropyridine calcium channel blockers (diltiazem, verapamil), and digoxin as causative agents 6.

  • Do not discontinue amlodipine in patients presenting with bradycardia, as it is not the causative agent 6.

  • Amlodipine can be safely combined with beta-blockers without concern for additive bradycardic effects, as demonstrated in multiple clinical trials 1.

  • The typical hemodynamic response to therapeutic amlodipine is vasodilation with either no change in heart rate or a slight reflex tachycardia, not bradycardia 1, 7.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

A Case of Life-threatening Amlodipine and Atenolol Overdose.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine, 2019

Guideline

Tamsulosin and Bradycardia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.